Annovis Bio, Inc. (ANVS)

NYSE: ANVS · Real-Time Price · USD

1.205

-0.055 (-4.37%)

Apr 17, 2025, 4:00 PM EDT - Market closed

Annovis Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Selling, General & Admin	6.7	6.24	9	6.06	3.59	Upgrade
Research & Development	20	38.79	16.52	8.48	3.05	Upgrade
Operating Expenses	26.69	45.04	25.51	14.54	6.64	Upgrade
Operating Income	-26.69	-45.04	-25.51	-14.54	-6.64	Upgrade
Interest & Investment Income	0.33	0.67	0.18	0.01	0.05	Upgrade
Other Non Operating Income (Expenses)	1.77	-11.84	-	0.04	1.13	Upgrade
Pretax Income	-24.59	-56.2	-25.33	-14.49	-5.46	Upgrade
Net Income	-24.59	-56.2	-25.33	-14.49	-5.46	Upgrade
Net Income to Common	-24.59	-56.2	-25.33	-14.49	-5.46	Upgrade
Shares Outstanding (Basic)	12	9	8	8	6	Upgrade
Shares Outstanding (Diluted)	12	9	8	8	6	Upgrade
Shares Change (YoY)	35.60%	10.55%	7.03%	20.88%	2132.36%	Upgrade
EPS (Basic)	-2.02	-6.23	-3.10	-1.90	-0.87	Upgrade
EPS (Diluted)	-2.31	-6.23	-3.10	-1.90	-0.87	Upgrade
EBIT	-26.69	-45.04	-25.51	-14.54	-6.64	Upgrade

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q